We are live on
!
Find out more
PP
PDT Partners Portfolio holdings
AUM
$1.69B
1-Year Est. Return
74.01%
This Fund
S&P 500
This Quarter
Est. Return
+21.19%
1 Year Est. Return
+74.01%
3 Year Est. Return
+179.69%
5 Year Est. Return
+210.81%
10 Year Est. Return
+1,321.68%
AUM
$1.77B
AUM Growth
-$20M
(-1.1%)
Cap. Flow
-$279M
Cap. Flow
% of AUM
-15.76%
Top 10 Holdings %
Top 10 Hldgs %
16.25%
Holding
547
New
90
Increased
94
Reduced
221
Closed
118
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$32.2M |
| 2 |
Agilent Technologies
A
|
+$10.1M |
| 3 |
Incyte
INCY
|
+$9.9M |
| 4 |
APC
Anadarko Petroleum
APC
|
+$9.65M |
| 5 |
ServiceNow
NOW
|
+$9.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Morgan Stanley
MS
|
+$22.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$19.6M |
| 3 |
Capri Holdings
CPRI
|
+$18.6M |
| 4 |
Delta Air Lines
DAL
|
+$17.6M |
| 5 |
Nutanix
NTNX
|
+$17.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.83% |
| 2 | Technology | 24.23% |
| 3 | Consumer Discretionary | 14.95% |
| 4 | Industrials | 7.4% |
| 5 | Financials | 7.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
AXIS Capital
AXS
$8.59B
| $4.28M | 0.24% |
+78,202
| New | +$4.33M |
|
|
ONCE
127
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $4.17M | 0.24% |
36,645
-157,174
| -81% | -$11.6M |
|
128
Wingstop
WING
$3.68B
| $4.15M | 0.23% |
54,600
| – | – |
|
|
AXON
129
Axon Enterprise
AXON
$40.5B
| $4.14M | 0.23% |
76,100
-33
| -0% | -$1.69K |
|
|
AMED
130
DELISTED
Amedisys
AMED
| $4.06M | 0.23% |
32,965
-31,200
| -49% | -$3.92M |
|
131
Hexcel
HXL
$8.32B
| $4.05M | 0.23% |
+58,508
| New | +$3.93M |
|
132
Green Dot
GDOT
$753M
| $4.04M | 0.23% |
66,700
-2,700
| -4% | -$188K |
|
133
Nu Skin
NUS
$247M
| $3.95M | 0.22% |
82,613
+7,313
| +10% | +$443K |
|
134
Boston Beer
SAM
$1.88B
| $3.93M | 0.22% |
+13,330
| New | +$3.65M |
|
135
United Parks & Resorts
PRKS
$2.11B
| $3.93M | 0.22% |
152,404
-31,629
| -17% | -$807K |
|
|
NVRO
136
DELISTED
NEVRO CORP.
NVRO
| $3.8M | 0.21% |
60,729
-26,383
| -30% | -$1.24M |
|
137
KBR
KBR
$4.68B
| $3.77M | 0.21% |
197,200
-64,902
| -25% | -$1.17M |
|
|
CLDR
138
DELISTED
Cloudera, Inc.
CLDR
| $3.7M | 0.21% |
338,506
+9,906
| +3% | +$127K |
|
139
Kosmos Energy
KOS
$1.56B
| $3.65M | 0.21% |
585,090
+69,381
| +13% | +$385K |
|
140
Trex
TREX
$4.51B
| $3.63M | 0.21% |
118,072
| – | – |
|
|
CORE
141
DELISTED
Core Mark Holding Co., Inc.
CORE
| $3.63M | 0.21% |
97,770
| – | – |
|
142
LivePerson
LPSN
$18.9M
| $3.57M | 0.2% |
8,201
-636
| -7% | -$238K |
|
143
Shake Shack
SHAK
$2.3B
| $3.55M | 0.2% |
60,000
-28,943
| -33% | -$1.48M |
|
|
HZNP
144
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.51M | 0.2% |
132,700
-59,500
| -31% | -$1.41M |
|
145
Pediatrix Medical
MD
$2.16B
| $3.42M | 0.19% |
125,974
+744
| +0.6% | +$24.9K |
|
|
UNVR
146
DELISTED
Univar Solutions Inc.
UNVR
| $3.42M | 0.19% |
154,119
-4
| -0% | -$86 |
|
147
TriNet
TNET
$2.84B
| $3.4M | 0.19% |
57,000
+6,649
| +13% | +$351K |
|
|
IPHI
148
DELISTED
INPHI CORPORATION
IPHI
| $3.38M | 0.19% |
77,300
+3,366
| +5% | +$134K |
|
149
Silicon Laboratories
SLAB
$7.15B
| $3.38M | 0.19% |
41,800
-2,700
| -6% | -$225K |
|
150
Alkermes
ALKS
$8.82B
| $3.35M | 0.19% |
91,847
-41,653
| -31% | -$1.38M |
|
Similar funds
ISS
GAM
BCM
FACM
TCBWMS
WAS
SGI
AAM
PDT Partners's Q1 2019 Portfolio in Review
As of Q1 2019, PDT Partners held 547 positions worth $1.77B, down 1.1% from $1.79B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
PDT Partners withdrew a net $279M in Q1 2019, closing 118 positions and reducing 221 holdings. Its most notable exit was Morgan Stanley, an estimated $22.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 25% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, PDT Partners opened a new position in Bristol-Myers Squibb worth $30.8M.
- PDT Partners's largest Q1 2019 buy was Bristol-Myers Squibb: 645,994 shares worth $30.8M.
- PDT Partners added most to Anadarko Petroleum in Q1 2019, an estimated $9.65M increase.
- PDT Partners's biggest Q1 2019 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $11.6M.
- PDT Partners fully exited Morgan Stanley in Q1 2019, selling an estimated $22.6M.
- PDT Partners's ten largest holdings make up 16% of its $1.77B portfolio in Q1 2019.
- PDT Partners opened 90 new positions and closed 118 in Q1 2019.
- PDT Partners's portfolio value fell 1.1% quarter-over-quarter to $1.77B.
Based on PDT Partners's 13F filing for Q1 2019, filed 15 May 2019.